These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 22546991

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
    Ellis JC, L'homme RF, Ewings FM, Mulenga V, Bell F, Chileshe R, Molyneux E, Abernethy J, van Oosterhout JJ, Chintu C, Walker AS, Gibb DM, Burger DM.
    Antivir Ther; 2007; 12(2):253-60. PubMed ID: 17503667
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
    Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, Kolladarungkri T, Vanprapar N.
    AIDS; 2005 Sep 23; 19(14):1495-9. PubMed ID: 16135903
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
    Prasitsuebsai W, Cressey TR, Capparelli E, Vanprapar N, Lapphra K, Chokephaibulkit K.
    Pediatr Infect Dis J; 2012 Apr 23; 31(4):389-91. PubMed ID: 22146740
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
    Mukherjee A, Singla M, Velpandian T, Sirohiwal A, Vajpayee M, Singh R, Kabra SK, Lodha R.
    Indian Pediatr; 2014 Mar 23; 51(3):191-7. PubMed ID: 24736906
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM, ANRS 12146-CARINEMO Study Group.
    Antimicrob Agents Chemother; 2014 Jun 23; 58(6):3182-90. PubMed ID: 24663014
    [Abstract] [Full Text] [Related]

  • 8. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
    L'homme RF, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, Walker AS, Chintu C, Burger DM, Gibb DM.
    AIDS; 2008 Mar 12; 22(5):557-65. PubMed ID: 18316996
    [Abstract] [Full Text] [Related]

  • 9. Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
    Enimil A, Antwi S, Yang H, Dompreh A, Alghamdi WA, Gillani FS, Orstin A, Bosomtwe D, Opoku T, Norman J, Wiesner L, Langaee T, Peloquin CA, Court MH, Greenblatt DJ, Kwara A.
    Antimicrob Agents Chemother; 2019 Oct 12; 63(10):. PubMed ID: 31332062
    [Abstract] [Full Text] [Related]

  • 10. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Matteelli A, Saleri N, Villani P, Bonkoungou V, Carvalho AC, Kouanda S, Sanou MJ, Simporé J, Monno L, Carosi G, Regazzi M, Dembele M.
    J Acquir Immune Defic Syndr; 2009 Sep 01; 52(1):64-9. PubMed ID: 19731452
    [Abstract] [Full Text] [Related]

  • 11. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
    Burger D, Ewings F, Kabamba D, L'homme R, Mulenga V, Kankasa C, Thomason M, Gibb DM, Chintu C, Walker AS.
    Ther Drug Monit; 2010 Jun 01; 32(3):369-72. PubMed ID: 20386361
    [Abstract] [Full Text] [Related]

  • 12. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
    Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, Prasitsuebsai W, Hongsiriwan S, Chotpitayasunondh T, Eksaengsri A, Toye M, Smith ME, McIntosh K, Capparelli E, Yogev R, IMPAACT P1056 Team.
    Pediatr Infect Dis J; 2010 Oct 01; 29(10):940-4. PubMed ID: 20453709
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
    Corbett AH, Hosseinipour MC, Nyirenda J, Kanyama C, Rezk NL, Mkupani P, Sichali D, Tien H, Kashuba AD, Mwansambo C, Weigel R, Kazembe P.
    Antivir Ther; 2010 Oct 01; 15(1):83-90. PubMed ID: 20167994
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US.
    Eur J Clin Pharmacol; 2009 Jan 01; 65(1):71-80. PubMed ID: 18751690
    [Abstract] [Full Text] [Related]

  • 15. Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.
    Poerksen G, Pollock L, Moons P, Chesshyre E, Burger D, Khoo S, Molyneux E.
    Antivir Ther; 2010 Jan 01; 15(3):343-50. PubMed ID: 20516554
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D, Ruxrungtham K.
    Antivir Ther; 2008 Jan 01; 13(4):529-36. PubMed ID: 18672531
    [Abstract] [Full Text] [Related]

  • 17. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
    McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, Msandiwa R, Wiesner L, Velaphi S, Lala SG, Chaisson RE, Martinson N, Dooley KE, Tshepiso Study Team.
    J Antimicrob Chemother; 2017 Jul 01; 72(7):2028-2034. PubMed ID: 28419277
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.
    Meyers T, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Denson K, Hovind L, Sise T, Teppler H, Mathiba SR, Masenya M, Hesseling A, Cotton MF, Krogstad P, IMPAACT P1101 Team.
    AIDS; 2019 Nov 15; 33(14):2197-2203. PubMed ID: 31689263
    [Abstract] [Full Text] [Related]

  • 19. Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
    Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Chintu C, Gibb DM, Walker AS, Burger DM, CHAPAS-1 trial team.
    AIDS; 2013 Aug 24; 27(13):2111-5. PubMed ID: 23595153
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
    Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocaña I, Ruiz I, Pahissa A.
    J Acquir Immune Defic Syndr; 2001 Dec 15; 28(5):450-3. PubMed ID: 11744833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.